Gabrielle Lakusta

Gabrielle grew up in the Lower Mainland of B.C. and has lived in Vancouver since 2011. She holds an Associate of Arts Degree from Langara College, and a Bachelors of Arts Major in Journalism from Kwantlen Polytechnic University. Now, she writes for INN focusing on Life Science Investing. Aside from work, Gabrielle enjoys travelling, and enjoying the outdoors—especially when hiking and cycling.

glakusta@resourceinvestingnews.com

Articles

Nuvectra Provides Update on Virtis FDA PMA Submission

Nuvectra (NASDAQ:NVTR), a medical device company dedicated to neuromodulation, announced today that the U.S. Food and Drug Administration (FDA) has...

January 30th, 2019

NeuroMetrix Reports New Clinical Studies Published on DPNCheck

NeuroMetrix (Nasdaq:NURO) reported publication of three new DPNCheck clinical studies. DPNCheck is a point-of-care test that provides accurate and cost-effective screening,...

January 30th, 2019

Healios Focusing on Stem Cell Trials in Asia

David Smith, director at Healios, talks about his company’s focus, stem cell trials and what the future holds.

January 29th, 2019

Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress

Altimmune (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced results of its recently completed HepTcell Phase 1 clinical trial will be...

January 29th, 2019

scPharmaceuticals Announces Development Agreement with West Pharmaceutical Services

scPharmaceuticals (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of...

January 29th, 2019

Cancer Genetics Announces Pricing of $3.5 Million Public Offering of Common Stock

Cancer Genetics (Nasdaq:CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today...

January 29th, 2019

Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism

Allakos (NASDAQ:ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive...

January 29th, 2019